GLP-1 medications, including semaglutide known as Ozempic, Wegovy, and Rybelsus, deliver weight loss and diabetes management benefits while also improving mental health outcomes. New research reveals users experience fewer psychiatric hospital visits and reduced work absences due to mental health issues.
Key Findings from Large-Scale Analysis
Researchers from the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia examined data from nearly 100,000 individuals, with over 20,000 using GLP-1 drugs. Swedish national health registers tracked participants from 2009 to 2022.
Obesity and diabetes often correlate with heightened mental health risks, and psychiatric conditions increase chances of metabolic disorders. This study explores how GLP-1 treatments impact mental well-being.
Significant Drops in Depression, Anxiety, and Care Needs
Semaglutide use links to a 42% reduction in psychiatric hospital visits and sickness absence compared to non-use periods. Depression risk falls by 44%, and anxiety disorders decrease by 38%.
Lower Substance Use Disorders and Suicidal Risks
Treatment periods show a 47% drop in hospital care and work absences tied to substance use disorders. GLP-1 receptor agonists also associate with reduced suicidal behavior risks.
Professor Mark Taylor from Griffith University notes, “An earlier study examining Swedish registers found the use of GLP-1 medications to be associated with a reduced risk of alcohol use disorder. Alcohol-related problems often have downstream effects on mood and anxiety, so we expected the effect to be positive on these as well.”
Potential Brain and Lifestyle Effects
The strong associations surprise the team. Research Director Docent Markku Lähteenvuo from the University of Eastern Finland explains, “Because this is a registry-based study, we cannot determine exactly why or how these medications affect mood symptoms, but the association was quite strong. It is possible that, in addition to factors such as reduced alcohol consumption, weight loss-related improvements in body image, or relief associated with better glycemic control in diabetes, there may also be direct neurobiological mechanisms involved — for example, through changes in the functioning of the brain’s reward system.”
Robust Evidence Calls for Further Study
The findings appear in The Lancet Psychiatry (2026; 13(4):327, DOI: 10.1016/S2215-0366(26)00014-3). While prior smaller studies yield mixed results, this large analysis provides compelling evidence, though additional research will clarify the connections.
